Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
04/22/2011
Trade Name:
Menactra
Generic or Proper Name (*):
Meningococcal Polysaccharide (Serogroups A, C, Y and W-135) Diphtheria Toxoid Conjugate Vaccine)*
Indications Studied:
Active immunization of individuals 9 months through 55 years of age for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135
Therapeutic Category:
Preventive Vaccine
Ages Studied:
9 - <13 months
Study #:
2
Study Type:
Safety/Immunogenicity
Study Design:
Randomized/Open label, Controlled
No Patients:
1664
No Centers:
92
No Countries:
1
BPCA(B), PREA(P):
P
Unknown:
0
-
-